Orthocell (OCC) Q4 2026 TU earnings summary

Executive summary

• Achieved record quarterly and annual revenue, with FY2026 revenue reaching $13.2 million, up 44% year-over-year, driven by strong U.S. Remplir and Striate+ sales and expanding international presence.

• U.S. distributor network expanded to over 20 states, covering 50% of the population, with increased adoption in Australia, Asia, and new distributor appointments in Canada and Thailand.

• Strong liquidity position with $44.1 million in cash and term deposits as of June 30, 2026, and no financial debt, supporting ongoing commercial and R&D activities.

• Expanded global reach with regulatory progress in the UK/EU and Latin America.

Financial highlights

• FY2026 revenue reached $13.2 million, up 44% year-over-year; Q4 FY2026 revenue was $3.8 million, up 20% sequentially and 36% year-over-year.

• U.S. Remplir Q4 FY2026 revenue was $0.33 million, up 10% quarter-over-quarter, with 70 hospitals and 76 surgeons using the product.

• Cash receipts from customers totaled $2.5 million for the quarter, up from $1.6 million in the prior quarter.

• Cash runway of 4.6 years based on current burn rate; $44.1 million available as of June 30, 2026.

• Net operating cash outflow of $3.7 million for the quarter, with normalised cash burn stable at $2.4 million after adjusting for non-recurring items.

Outlook and guidance

• Anticipates continued revenue growth in FY2027, driven by further U.S. hospital adoption and surgeon utilisation.

• Targets for FY27 include 80% U.S. distributor coverage, 100-150 cumulative hospitals, and 150-200 cumulative surgeons using Remplir.

• Regulatory approval for Remplir in the UK/EU expected by end of CY2026, unlocking a major market.

• Commercial launches of Striate+ in Brazil, Colombia, and Ecuador expected in 2H CY2026.

• U.S. regulatory program for a tendon repair application underway, expanding the addressable market.